99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors

Trogrlić, Mate; Težak, Stanko

doi:10.5603/nmr.2016.0016

Cited by 5 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…99m Tc-labeled hydrazinonicotinyl-Tyr3-octreotide (EDDA/HYNIC-TOC) is commonly used for the management of neuroendocrine tumors (NET) [10–12]. Although the 68 Ga-DOTA-somatostatin analogue PET/CT is now the recommended standard method for imaging, staging and restaging most types of NET [13,14], the 99m Tc-labeled platform represents a good alternative to Gallium-68 radiotracers where PET/CT or Gallium-68 generators are not available [15]. …”

Section: Different Radioisotopes For Imagingmentioning

confidence: 99%

The role of radionuclide probes for monitoring anti-tumor drugs efficacy: A brief review

Fernandes

Ferreira

Soares

et al. 2017

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Despite recent advances in the development of new therapeutic agents and diagnostic imaging modalities, cancer is still one of the main causes of death worldwide. A better understanding of the molecular signature of cancer has promoted the development of a new generation of anti-cancer drugs and diagnostic agents that specifically target molecular components such as genes, ligands, receptors and signaling pathways. However, intrinsic heterogeneity of tumors has hampered the overall success of target therapies even among patients with similar tumor types but unpredictable different responses to therapy. In this sense, post-treatment response monitoring becomes indispensable and nuclear medicine imaging modalities could provide the tools for an early indication of therapeutic efficacy. Herein, we briefly discuss the current role of PET and SPECT imaging in monitoring cancer therapy together with an update on the current radiolabeled probes that are currently investigated for tumor therapy response assessment.

show abstract

Section: Different Radioisotopes For Imagingmentioning

confidence: 99%

The role of radionuclide probes for monitoring anti-tumor drugs efficacy: A brief review

Fernandes

Ferreira

Soares

et al. 2017

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…At the beginning of this century, two new 99m Tc-labelled SST analogues were introduced: [ 99m Tc]Tc-N4-[Tyr3] Octreotate (Demotate ® , POLATOM, Otwock, Poland) and [ 99m Tc]Tc-EDDA/HYNIC-[Tyr3] Octreotide (Tektrotyd ® , POLATOM, Otwock, Poland) [11], both of which are widely used in clinical practice with major advantages over [ 111 In]In-Octreotide [12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27].…”

Section: Introductionmentioning

confidence: 99%

Role of Combined [68Ga]Ga-DOTA-SST Analogues and [18F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review

Carideo

Prosperi

Panzuto

et al. 2019

JCM

View full text Add to dashboard Cite

Gastro-entero-pancreatic neuroendocrine neoplasia (GEP-NENs) are rare tumors, but their frequency is increasing. Neuroendocrine tumors normally express somatostatin (SST) receptors (SSTR) on cell surface, especially G1 and G2 stage tumors, but they can show a dedifferentiation in their clinical history as they become more aggressive. Somatostatin receptor imaging has previously been performed with a gamma camera using [111In]In or [99mTc]Tc-labelled compounds, while [68Ga]Ga-labelled compounds and PET/CT imaging has recently become the gold standard for the diagnosis and management of these tumors. Moreover, in the last few years 18F-fluorodeoxyglucose ([18F]FDG) PET/CT has emerged as an important tool to define tumor aggressiveness and give relevant prognostic information, particularly when coupled with [68Ga]Ga-labelled SST analogues PET/CT. This review focuses on the importance of combined imaging with [68Ga]Ga-labelled SST analogues and [18F]FDG for the management of GEP-NENs.

show abstract

Radiopharmaceutical Sciences

Neumaier

Benešová

Hugenberg

et al. 2020

Clinical Nuclear Medicine

View full text Add to dashboard Cite

99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors

Abstract: BACKGROUND: Aim of this study was to determine the value of technetium-99m-hydrazinonicotinyl-Tyr3-octreotide (

Cited by 5 publications

References 23 publications

The role of radionuclide probes for monitoring anti-tumor drugs efficacy: A brief review

The role of radionuclide probes for monitoring anti-tumor drugs efficacy: A brief review

Role of Combined [68Ga]Ga-DOTA-SST Analogues and [18F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review

Radiopharmaceutical Sciences

Contact Info

Product

Resources

About